The loss of patents on big revenue-generating medicines continued to weigh on AstraZeneca Plc as first-quarter revenue declined by 12% at constant exchange rates to $6.4 billion and core operating profit declined by 21% to $2.3 billion. The company expects that revenue for the year as a whole will decline by a mid-to-high single digit percentage.
